Literature DB >> 15755075

Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination.

Qiyuan Chen1, Heather Jackson, Mark Shackleton, Phillip Parente, Wendie Hopkins, Sue Sturrock, Duncan MacGregor, Eugene Maraskovsky, Tsin Yee Tai, Nektaria Dimopoulos, Kelly-Anne Masterman, Tina Luke, Ian D Davis, Weisan Chen, Jonathan Cebon.   

Abstract

Immune responses to cancer vaccines are commonly tested by measuring cutaneous reactions to intradermal (i.d.) antigen. When well-characterized peptide epitopes are injected i.d., infiltrates of CD4+ and CD8+ T lymphocytes are frequently seen. In this study, we have further characterized T cells derived from vaccine-infiltrating lymphocyte (VIL) responses. We found that the infiltrates capable of producing IFN-gamma and cytolytic activity could recognize vaccine peptide, as well as antigen-positive melanoma cells. We studied antigen-specific T cell responses from VILs and peripheral blood in 10 patients who participated in a clinical trial. All patients received systemic Flt3 ligand (20 microg/kg/d) and i.d. peptides: Three NY-ESO-1 peptides, SLLMWITQCFL (157-167), SLLMWITQC (157-165), QLSLLMWIT (155-163); tyrosinase internal peptide YMDGTMSQV (368-376); Melan-A/MART-1 analogue peptide ELAGIGILTV (26-35, E27L substitution); and influenza matrix peptide GILGFVFTL (58-66). In 54 paired VIL and peripheral blood analyses, a good correlation was found between responses in skin and in blood. These cells could be rapidly expanded in a short-term assay and thus appear to be memory T cells. The demonstrated presence of antigen-specific T cells at vaccination sites validates this method of assessing the immune response to i.d. vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15755075

Source DB:  PubMed          Journal:  Cancer Immun        ISSN: 1424-9634


  10 in total

1.  Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.

Authors:  Jennifer A Wargo; Paul F Robbins; Yong Li; Yangbing Zhao; Mona El-Gamil; Diana Caragacianu; Zhili Zheng; Julie A Hong; Stephanie Downey; David S Schrump; Steven A Rosenberg; Richard A Morgan
Journal:  Cancer Immunol Immunother       Date:  2008-08-02       Impact factor: 6.968

2.  Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor.

Authors:  David K Cole; Fang Yuan; Pierre J Rizkallah; John J Miles; Emma Gostick; David A Price; George F Gao; Bent K Jakobsen; Andrew K Sewell
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

3.  Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas.

Authors:  Jean-Philippe Carralot; Benjamin Weide; Oliver Schoor; Jochen Probst; Birgit Scheel; Regina Teufel; Ingmar Hoerr; Claus Garbe; Hans-Georg Rammensee; Steve Pascolo
Journal:  Genet Vaccines Ther       Date:  2005-08-22

4.  SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade.

Authors:  Wei Xue; Rachael L Metheringham; Victoria A Brentville; Barbara Gunn; Peter Symonds; Hideo Yagita; Judith M Ramage; Lindy G Durrant
Journal:  Oncoimmunology       Date:  2016-04-22       Impact factor: 8.110

Review 5.  Cancer testis antigen and immunotherapy.

Authors:  Deepa Kolaseri Krishnadas; Fanqi Bai; Kenneth G Lucas
Journal:  Immunotargets Ther       Date:  2013-04-17

Review 6.  Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire.

Authors:  Sebastian P Haen; Markus W Löffler; Hans-Georg Rammensee; Peter Brossart
Journal:  Nat Rev Clin Oncol       Date:  2020-06-22       Impact factor: 66.675

7.  TCR-induced alteration of primary MHC peptide anchor residue.

Authors:  Florian Madura; Pierre J Rizkallah; Mateusz Legut; Christopher J Holland; Anna Fuller; Anna Bulek; Andrea J Schauenburg; Andrew Trimby; Jade R Hopkins; Stephen A Wells; Andrew Godkin; John J Miles; Malkit Sami; Yi Li; Nathaniel Liddy; Bent K Jakobsen; E Joel Loveridge; David K Cole; Andrew K Sewell
Journal:  Eur J Immunol       Date:  2019-05-27       Impact factor: 5.532

8.  Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition.

Authors:  David K Cole; Emily S J Edwards; Katherine K Wynn; Mathew Clement; John J Miles; Kristin Ladell; Julia Ekeruche; Emma Gostick; Katherine J Adams; Ania Skowera; Mark Peakman; Linda Wooldridge; David A Price; Andrew K Sewell
Journal:  J Immunol       Date:  2010-07-16       Impact factor: 5.422

9.  T-cell receptor-optimized peptide skewing of the T-cell repertoire can enhance antigen targeting.

Authors:  Julia Ekeruche-Makinde; Mathew Clement; David K Cole; Emily S J Edwards; Kristin Ladell; John J Miles; Katherine K Matthews; Anna Fuller; Katy A Lloyd; Florian Madura; Garry M Dolton; Johanne Pentier; Anna Lissina; Emma Gostick; Tiffany K Baxter; Brian M Baker; Pierre J Rizkallah; David A Price; Linda Wooldridge; Andrew K Sewell
Journal:  J Biol Chem       Date:  2012-09-05       Impact factor: 5.157

Review 10.  Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.

Authors:  Afsheen Raza; Maysaloun Merhi; Varghese Philipose Inchakalody; Roopesh Krishnankutty; Allan Relecom; Shahab Uddin; Said Dermime
Journal:  J Transl Med       Date:  2020-03-27       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.